These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 32870351)
1. Future perspective: high-throughput construction of new ultrasensitive cytokine and virion liquid chips for high-throughput screening (HTS) of anti-inflammatory drugs or clinical diagnosis and treatment of inflammatory diseases. Feng Y; Huang J; Qu C; Huang M; Chen Z; Tang D; Xu Z; Wang B; Chen Z Anal Bioanal Chem; 2020 Nov; 412(28):7685-7699. PubMed ID: 32870351 [TBL] [Abstract][Full Text] [Related]
2. High-Throughput Chip Assay for Investigating Escherichia coli Interaction with the Blood-Brain Barrier Using Microbial and Human Proteome Microarrays (Dual-Microarray Technology). Feng Y; Chen CS; Ho J; Pearce D; Hu S; Wang B; Desai P; Kim KS; Zhu H Anal Chem; 2018 Sep; 90(18):10958-10966. PubMed ID: 30106562 [TBL] [Abstract][Full Text] [Related]
3. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381 [TBL] [Abstract][Full Text] [Related]
4. The Development of Protein Chips for High Throughput Screening (HTS) of Chemically Labeling Small Molecular Drugs. Feng Y; Wang B; Chu X; Wang Y; Zhu L Mini Rev Med Chem; 2016; 16(10):846-50. PubMed ID: 25963567 [TBL] [Abstract][Full Text] [Related]
5. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
6. High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro. Gard AL; Luu RJ; Miller CR; Maloney R; Cain BP; Marr EE; Burns DM; Gaibler R; Mulhern TJ; Wong CA; Alladina J; Coppeta JR; Liu P; Wang JP; Azizgolshani H; Fezzie RF; Balestrini JL; Isenberg BC; Medoff BD; Finberg RW; Borenstein JT Sci Rep; 2021 Jul; 11(1):14961. PubMed ID: 34294757 [TBL] [Abstract][Full Text] [Related]
7. Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19. Tan DX; Hardeland R Molecules; 2020 Sep; 25(19):. PubMed ID: 32992875 [TBL] [Abstract][Full Text] [Related]
8. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H Elife; 2020 Apr; 9():. PubMed ID: 32338605 [TBL] [Abstract][Full Text] [Related]
9. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. González-Pacheco H; Amezcua-Guerra LM; Sandoval J; Arias-Mendoza A Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7494-7496. PubMed ID: 32706089 [TBL] [Abstract][Full Text] [Related]
10. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322 [TBL] [Abstract][Full Text] [Related]
11. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity. Drew ED; Janes RW BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313 [TBL] [Abstract][Full Text] [Related]
12. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors. Romeo A; Iacovelli F; Falconi M Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126 [TBL] [Abstract][Full Text] [Related]
13. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
14. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. Zhu Y; Yu D; Yan H; Chong H; He Y J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627 [TBL] [Abstract][Full Text] [Related]
15. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Conti P; Ronconi G; Caraffa A; Gallenga CE; Ross R; Frydas I; Kritas SK J Biol Regul Homeost Agents; 2020 March-April,; 34(2):327-331. PubMed ID: 32171193 [TBL] [Abstract][Full Text] [Related]
16. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052 [TBL] [Abstract][Full Text] [Related]
17. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Chen J; Wang YK; Gao Y; Hu LS; Yang JW; Wang JR; Sun WJ; Liang ZQ; Cao YM; Cao YB Biomed Pharmacother; 2020 Sep; 129():110281. PubMed ID: 32554251 [TBL] [Abstract][Full Text] [Related]
18. How to Discover Antiviral Drugs Quickly. Parks JM; Smith JC N Engl J Med; 2020 Jun; 382(23):2261-2264. PubMed ID: 32433861 [No Abstract] [Full Text] [Related]
19. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
20. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. Conti P; Gallenga CE; Tetè G; Caraffa A; Ronconi G; Younes A; Toniato E; Ross R; Kritas SK J Biol Regul Homeost Agents; 2020 March-April,; 34(2):333-338. PubMed ID: 32228825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]